REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals (REGN) Business News

Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
11:06 AM | Thursday | Jul 23, 2026 Zacks Investment Research

Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

News Thumbnail
10:09 AM | Thursday | Jul 23, 2026 PRNewsWire

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

News Thumbnail
10:05 AM | Thursday | Jul 23, 2026 Business Wire

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

News Thumbnail
10:00 AM | Thursday | Jul 23, 2026 Newsfile Corp

Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN

News Thumbnail
10:00 AM | Thursday | Jul 23, 2026 PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

News Thumbnail
9:33 AM | Thursday | Jul 23, 2026 GlobeNewsWire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

News Thumbnail
7:06 AM | Thursday | Jul 23, 2026 Business Wire

REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

News Thumbnail
12:00 PM | Wednesday | Jul 22, 2026 PRNewsWire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

News Thumbnail
12:00 PM | Wednesday | Jul 22, 2026 Newsfile Corp

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

News Thumbnail
9:22 AM | Wednesday | Jul 22, 2026 GlobeNewsWire

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

News Thumbnail

Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks Investment Research

11:06 AM | Thursday | Jul 23, 2026

news photo
Loading...

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read full article redirect
11:06 AM | Thursday | Jul 23, 2026

Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks Investment Research

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read full article arrow
News Thumbnail
10:09 AM | Thursday | Jul 23, 2026

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

PRNewsWire

Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis. NEW YORK, July 23, 2026 /PRNewswire/ -- SueWallSt alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased REGN securities between August 1, 2025 and May 15, 2026.

Read full article arrow
News Thumbnail
10:05 AM | Thursday | Jul 23, 2026

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Business Wire

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Find out if you might be eligible to recover losses. You may also contact Joseph E. Levi, Esq.
at jlevi@levikorsinsky.com or (212) 363-7500. REGN traded as high as $731.77 on April 28, 2026 and closed at $629.68 after the Company announced t.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Jul 23, 2026

Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN

Newsfile Corp

San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Jul 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

PRNewsWire

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read full article arrow
News Thumbnail
9:33 AM | Thursday | Jul 23, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

GlobeNewsWire

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025 and May 15, 2026, inclusive. Should You Join The Regeneron Class Action Lawsuit : Do you, or did you, own shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)?

Read full article arrow
News Thumbnail
7:06 AM | Thursday | Jul 23, 2026

REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Business Wire

NEW YORK--(BUSINESS WIRE)---- $REGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California an.

Read full article arrow
News Thumbnail
12:00 PM | Wednesday | Jul 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

PRNewsWire

NEW YORK, July 22, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period").

Read full article arrow
News Thumbnail
12:00 PM | Wednesday | Jul 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Newsfile Corp

New York, New York--(Newsfile Corp. - July 22, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

Read full article arrow
News Thumbnail
9:22 AM | Wednesday | Jul 22, 2026

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

GlobeNewsWire

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of the  September 14, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Regeneron Class Action Lawsuit : Do you, or did you, own shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)?

Read full article arrow
News Thumbnail